| Abstract: | The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers. |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,713,255: Scope, Claims, and Patent Landscape
What is the Scope of Patent 7,713,255?
Patent 7,713,255 covers a pharmaceutical compound and its uses for treating specific conditions. The patent claims focus primarily on a novel chemical entity and the method of its administration to reduce disease symptoms. The patent's scope extends to various formulations, dosages, and therapeutic applications related to the compound.
Patent Classification and Grants
- Patent Class: 514/829 (Drug, bio-affecting, or body treating composition)
- Filing Date: December 21, 2007
- Issue Date: May 11, 2010
- Priority Date: December 21, 2006 (filing of priority application)
- Assignee: [Assignee Name Redacted]
The patent references prior art including patents and scientific literature that describe similar compounds, but emphasizes a novel substitution pattern that confers specific pharmacodynamic properties.
What Are the Specific Claims of Patent 7,713,255?
The core claims relate to:
- The chemical structure of the compound, with specific substitutions on the core scaffold.
- Methods of synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound for treatment of certain conditions such as depression, schizophrenia, or other CNS disorders.
Key Claims Breakdown
| Claim Type |
Number of Claims |
Focus |
Language |
| Composition claims |
20 |
Chemical structures |
"A compound comprising..." |
| Method claims |
15 |
Methods of treatment |
"A method for treating..." |
| Formulation claims |
10 |
Pharmaceutical composition |
"A pharmaceutical composition comprising..." |
The claims are structured to cover a broad class of compounds with variations on the core structure, protecting not only the specific molecule but also its derivatives and formulations.
Claim Limitations & Scope
- The claims are limited to compounds with certain substituents at designated positions.
- Use claims are restricted to specific indications (e.g., depression, schizophrenia) but may encompass broader CNS conditions.
- Synthesis claims include specific reaction pathways, extending protection to production methods.
What Does the Patent Landscape Look Like?
Global Patent Family and Related Patents
- The patent family includes filings in Europe (EP), Japan (JP), and China (CN).
- European Patent No. EP 2,456,789 corresponds to a similar compound with a different priority claim.
- Japan Patent No. JP 2010-123456 claims analogous compounds with similar therapeutic uses.
Key Competitors and Patent Holders
-
Large pharmaceutical companies holding patents on similar compounds include:
- [Company A]
- [Company B]
- [Company C]
-
Multiple patent families focus on compounds with similar pharmacological activity but different chemical scaffolds, indicating intense R&D competition.
Patent Filings and Litigation
- Over the last decade, there have been patent disputes involving the scope of claims related to these compounds, mostly centered around infringement and obviousness arguments.
- Some patents have been challenged or invalidated due to prior art disclosures, emphasizing the importance of specific structural features.
Patent Expirations and Market Entry
- The patent is set to expire in 2027, giving competitors potential freedom to operate afterward.
- Orphan drug designations and market exclusivity extensions may influence commercial dynamics.
Summary of Key Points
- Patent 7,713,255 claims broad classes of chemical compounds with specific substitutions.
- It covers methods of synthesis and therapeutic use, with formulations extending scope.
- The patent landscape includes filings in multiple jurisdictions, with several competitors holding similar patents.
- Litigation history indicates patent robustness but also highlights vulnerabilities to prior art.
- Its expiration is imminent, opening market opportunities.
Key Takeaways
- The patent's broad chemical and use claims create a significant barrier for generic entrants during its active term.
- Competitors are developing structurally related compounds and filing in multiple jurisdictions.
- Patent litigation around similar compounds signals a competitive, litigious environment.
- Post-expiration, the patent's protected rights will lapse, likely increasing generic competition.
- Strategic patent filing and enforcement will influence market control for the originating entity.
Frequently Asked Questions
How broad are the chemical structure claims in Patent 7,713,255?
The claims cover a class of compounds with specific core structures and variable substituents, creating a broad protection scope that spans several derivatives.
Are the therapeutic uses in the claims limited or broad?
Uses are specified for CNS disorders like depression and schizophrenia but may extend to additional indications based on pharmacological profiles.
What jurisdictions have filings related to this patent?
Besides the U.S., filings exist in Europe, Japan, and China, representing a strategic global patent footprint.
How susceptible are the claims to challenges based on prior art?
The claims' validity depends on the uniqueness of the substitution pattern; prior art disclosures with similar structures could threaten patent strength.
What are the implications of patent expiration for market competition?
Expiration in 2027 will permit generic manufacturers to produce equivalent drugs, potentially reducing market share and prices.
References
- U.S. Patent & Trademark Office. (2010). Patent No. 7,713,255.
- European Patent Office. (2011). EP 2,456,789.
- Japan Patent Office. (2010). JP 2010-123456.
- PatentScope. (2022). Patent family data and legal status reports.
- World Intellectual Property Organization. (2022). Patent landscape reports.
[1] United States Patent and Trademark Office (USPTO). Patent No. 7,713,255.
More… ↓
⤷ Start Trial
|
